Previous close | 0.0620 |
Open | 0.0620 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 900 |
Day's range | 0.0620 - 0.0657 |
52-week range | 0.0310 - 0.7200 |
Volume | |
Avg. volume | 54,532 |
Market cap | 4.449M |
Beta (5Y monthly) | 1.22 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.